US20170273900A1 - Methods for manufacturing implants - Google Patents
Methods for manufacturing implants Download PDFInfo
- Publication number
- US20170273900A1 US20170273900A1 US15/618,339 US201715618339A US2017273900A1 US 20170273900 A1 US20170273900 A1 US 20170273900A1 US 201715618339 A US201715618339 A US 201715618339A US 2017273900 A1 US2017273900 A1 US 2017273900A1
- Authority
- US
- United States
- Prior art keywords
- mixture
- mixing
- sheath
- inner core
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C51/00—Shaping by thermoforming, i.e. shaping sheets or sheet like preforms after heating, e.g. shaping sheets in matched moulds or by deep-drawing; Apparatus therefor
- B29C51/12—Shaping by thermoforming, i.e. shaping sheets or sheet like preforms after heating, e.g. shaping sheets in matched moulds or by deep-drawing; Apparatus therefor of articles having inserts or reinforcements
-
- B29C47/0011—
-
- B29C47/028—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/04—Particle-shaped
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/15—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor incorporating preformed parts or layers, e.g. extrusion moulding around inserts
- B29C48/157—Coating linked inserts, e.g. chains
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2067/00—Use of polyesters or derivatives thereof, as moulding material
- B29K2067/04—Polyesters derived from hydroxycarboxylic acids
- B29K2067/046—PLA, i.e. polylactic acid or polylactide
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/712—Containers; Packaging elements or accessories, Packages
- B29L2031/7148—Blood bags, medical bags
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/754—Pessaries
Definitions
- Solid drug delivery implants are utilized to provide sustained release of an active agent or drug over a period of days, weeks, months, or years as an attractive alternative to more conventional dosage forms, such as oral or parenteral dosages.
- a few examples of such products include subcutaneous “rod” implants, intrauterine devices, and intravaginal rings (IVRs).
- IVRs intravaginal rings
- a preferred approach is to embed the drug within a polymer matrix of material and encapsulate it within a polymer membrane or sheath to provide a barrier for controlled drug diffusion and release.
- the drug is incorporated into the polymer by a hot melt extrusion process to produce drug-doped pellets.
- this disclosure describes techniques for manufacturing active ingredient cores. Techniques further describe methods for laminating active ingredient cores to form a rate-controlling sheath. In particular, this disclosure describes techniques for manufacturing subcutaneous implants, intrauterine devices, and intravaginal rings (IVRs), although it should be noted that the techniques of this disclosure are generally applicable to pharmacologically active implants.
- IVRs intravaginal rings
- a method of forming a pharmacologically active homogenous core matrix mixture comprises combining one or more polymers with one or more active ingredients to form a mixture; and mixing the mixture sufficient to impart heat and until a homogenous mixture is achieved; wherein heat imparted to the mixture is sufficient to melt the polymer without substantially altering the pharmacological properties of the active ingredient.
- a method of forming a rate-controlling release membrane over a pharmacologically active core comprises positioning a core between two layers film; applying one or more of heat and pressure to the core and film layers such that each film layer mechanically combines with one or more of the ring-shaped core and the opposite membrane film; and trimming excess film to form a sheath having a substantially uniform thickness.
- FIG. 1 illustrates a cross sectional side view of a ring-shaped implant, according to one or more embodiments of this disclosure.
- FIG. 2 illustrates a method for forming an inner core, according to one or more embodiments of this disclosure.
- FIG. 3A illustrates a method for laminating an inner core, according to one or more embodiments of this disclosure.
- FIG. 3B illustrates a perspective view of an inner core being positioned between sheath materials, according to one or more embodiments of this disclosure.
- FIG. 3C illustrates a perspective view of a post-combining product, according to one or more embodiments of this disclosure.
- FIG. 3D illustrates a cross-sectional view of a post-combining product, according to one or more embodiments of this disclosure.
- FIG. 3E illustrates a cross-sectional view of a post-combining product with excess material identified, according to one or more embodiments of this disclosure.
- implant can refer to an object which contacts the body of an animal or human, or an object which is positioned within an organ or an orifice.
- an implant can be positioned within a mouth, within a vagina, underneath an epidermis, or within a uterus. Examples of bodily positions are non-limiting; embodiments provided herein can be utilized throughout a body as necessary or advantageous.
- Implants can include subcutaneous implants, intrauterine devices, and intravaginal rings (IVRs).
- FIG. 1 illustrates a cross-sectional side view of an implant 100 , comprising an inner core 110 and a rate-controlling sheath 120 .
- Inner core 110 can comprise one or more polymer excipients and at least one active ingredient.
- the polymer fraction forms a matrix throughout which the one or more active ingredients are dispersed.
- the active ingredient is substantially uniformly dispersed, such as having a material uniformity less than +/ ⁇ 5%, less than +/ ⁇ 4%, less than +/ ⁇ 3%, less than +/ ⁇ 2%, or less than +/ ⁇ 1%.
- Polymers can include thermoplastics such as thermoplastic urethanes, polyethylene terephthalate polyesters, silicone thermoplastics, LTV silicone elastomers, and polyamides.
- polymers can include polyoxymethylene, thermoplastic copolyester elastomer (TPC-ET), polyethylene homopolymer, poly(vinyl acetate) homopolymer, poly(lactic acid) homopolymer, poly(caprolactone), polypropylene, poly(ethylene oxide), poly(styrene), poly(vinyl chloride) poly lactic-co-glycolic acid, and ethylene vinyl acetate (EVA).
- EVA comprises ethylene and vinyl acetate, with a weight percent (wt. %) of vinyl acetate ranging from about 5 wt. % to about 40 wt. %, about 7 wt. % to about 34 wt. %, or about 9 wt. % to about 28 wt. %.
- Active ingredients can include any pharmacologically active agents, such as contraceptive hormones.
- Contraceptive hormones can include estradiol, ethinyl estradiol, etonogestrel, progesterone, ethisterone, norethisterone acetate, norethynodrel, levonorgestrel, or gestodene, although others are similarly suitable as would be recognized by one of skill in the art after review of this disclosure.
- Inner core 110 can further comprise opacifiers, such as barium sulfate, or dyes.
- Inner core 110 can have a cross-sectional shape which is circular, or polygonal. In some embodiments, a cross-sectional shape is chosen to accommodate manufacturing processes or equipment.
- the overall shape of the inner core 110 can be tubular or rod shaped, or a continuous shape.
- a continuous shape can include a circle, oval, triangle, square, or other polygons. Shapes can include a mixture of straight and curved edges, such as a semi-circle. Shapes can include irregular geometries which can be in some embodiments designed to match the contour of an implant positioning location within a body.
- Rate-controlling sheath 120 can comprise one or more polymers, such as those suitable for the inner core 110 . Rate-controlling sheath 120 can comprise a similar composition to the polymer fraction of the inner core 110 . In some embodiments, rate-controlling sheath 120 and inner core 110 share at least one common polymer component. Composition of the rate-controlling sheath can be determined based on permeability of one or more active ingredients. In some embodiments, the compositions of the rate-controlling sheath 120 is selected such that the rate controlling-sheath 120 can melt. Accordingly, in some embodiments, polymers such as silicone are not suitable for the rate-controlling sheath 120 . In some embodiments, the rate-controlling sheath has a thickness of between about 1 mil to about 25 mils (about 0.0254 mm to about 0.635 mm).
- a method 200 of forming an inner core can comprise low-heat mixing 210 inner core components to form a mixture, processing 220 the mixture after mixing, and forming the inner core 230 .
- Inner core components can be supplied for mixing in powdered, pelleted, or liquid forms.
- One or more objectives of mixing 210 include removing air bubbles from the mixture, homogenizing the mixture to achieve suitable uniformity, elevating the temperature of the mixture above a melting point of at least one polymer. “Melting point” as used herein can refer to a melting point or a glass transition temperature. Homogenizing the mixture includes evenly dispersing the one or more active ingredients throughout the mixture.
- Mixing 210 can be accomplished via asymmetric mixing, wherein friction of mixing imparts heat on the mixture such that at least one polymer exceeds its melting point.
- Asymmetric mixing advantageously imparts sufficient heat onto the mixture, while the heat of the mixture remains below a damaging heat threshold.
- Active ingredients such as estradiol
- Asymmetric mixing is contactless, and relies on the movement of the vessel to initiate rapid spinning and shearing of a mixture contained within a vessel.
- contactless describes the relationship between a mixture and a mixer wherein the only component contacting the mixture is the vessel. This is in contrast to other mixing methods, which use paddles, screws, or other mixing elements to which contact and mix a mixture.
- Asymmetric mixing can include dual asymmetric mixing. Speed and duration of mixing is controlled to achieve mixing objectives.
- Vessels can be composed of a range of materials, including polypropylene, thermoplastic polyurethanes, glass, metals such as stainless steel or aluminum, polyethylene, polytetrafluoroethylene, or other suitable container materials.
- the vessel can comprise a number of materials which are disposable or reusable. Dual planetary mixers can be used. Examples of mixers include FlackTek SpeedMixersTM and Thinky mixers.
- Processing 220 can include allowing the mixture to cool under ambient conditions, or cooling the mixture using refrigerants, liquid nitrogen, or the like. Processing 220 can further comprise forming the cooled mixture into powders, granules, pellets, or pieces. An objective of processing 220 is to achieve a particle size which is suitable for forming 230 the inner core. In some embodiments a suitable particle diameter is less than 3 inches, less than 2 inches, or less than 1 inch. Forming the inner core 230 can comprise injection molding, although other methods can be suitable. An objective of forming the inner core 230 includes remaining below a damaging heat threshold.
- a method 300 of laminating an inner core can comprise positioning 310 an inner core between two surfaces of rate-controlling sheath material, combining 320 the inner core and sheath material, and trimming 330 excess sheath material.
- FIG. 3B shows an inner core 110 being positioned 310 between sheath materials 121 and 122 .
- Sheath materials such as 121 and 122 , can be supplied in films with varying thicknesses.
- sheath materials comprise a single sheet (not picture) which is folded about an inner core 110 .
- Combining 320 the inner core and sheath material can comprise thermal and/or pressure lamination.
- lamination to create dosage forms for pharmaceuticals is novel in the industry, as coextrusion has been the manufacturing method of choice due to familiarity of the technology. In instances where lamination has been employed, the same has been used solely to affect surfaces properties (e.g., wear, resistance, feel, etc.) of products. Lamination can be preferable to coextrusion as it is time efficient, heat and material efficient, and allows for superior operating temperature management and control and uniformity of sheath thickness. Controlling sheath uniformity and thickness is critical as it directly impacts drug release rates and overall implant efficacy and safety. Lamination additionally allows for thinner sheaths to be manufactured, increasing functionality of implants (e.g., drug release rates and use duration). Further, lamination encapsulates an inner core ring as a whole, rather than utilizing a welded joint which can affect drug release rate.
- Lamination according to method 300 can be conducted at high pressures, such as at 15 to 20 tons of force.
- Temperature can include temperatures above the film material's melting point. For example, when EVA is a film component, temperatures of 100-120 C can be used. In many embodiments, an operating temperature exceeds the melting point of one or more polymers by less than about 1% of the melting point temperature, less than about 2.5% of the melting point temperature, less than about 5% of the melting point temperature, or less than about 10% of the melting point temperature.
- a temperature can be chosen to exceed the melting point of one polymer component, of a plurality of polymer components, or all polymer components. A temperature can also be chosen such that the melting point of a core component is not exceeded.
- lamination process time and/or compressing pressure can be chosen to complement the process temperature in order to avoid chemical degradation and/or physical deformation of the core.
- Films can combine by one or more of adhering to the opposite film, or adhering to the inner core 110 .
- FIG. 3C illustrates a post combining 320 product 325 .
- FIG. 3D illustrates a cross-sectional view of a post-combing 320 product 325 which comprises an inner core 110 and a rate-controlling sheath 120 .
- FIG. 3E illustrates a cross-sectional view of a post-combining 320 product 325 , wherein excess sheath material 125 is identified.
- Excess material 125 can be defined as material not substantially contributing to an extrapolated contour of the core. Excess material can also be defined as material which does not provide a consistent sheath thickness. Trimming 330 excess sheath material can be accomplished using a die cutting system, or other suitable means.
- ethylene vinyl acetate (28% vinyl acetate content) polymer pellets or granules
- 50-250 mg of sex hormones such as ethinyl estradiol and/or etonorgestrel powder or opacifier such as barium sulfate were added.
- the container was placed in a dual asymmetric mixer (Flaktek SpeedMixer) and mixed for 2-10 minutes at up to 3000 RPM.
- the EVA had melted (estimated temperature 100-120° C.) and the drug was uniformly dispersed throughout the melt.
- Drug content analysis performed using inductively coupled plasma—optical emission spectroscopy revealed that material uniformity was approximately +/ ⁇ 2 %.
- the material was processed into granular materials suitable for injection molding by cooling the polymer and processing using with an IKA bladed mill.
- EVA EVA
- the polymer was cooled using liquid nitrogen before and/or during milling. Following milling, particle size was generally less than 0.75 in diameter, though many smaller particles were present.
- this ground material was transferred to an injection molding press and vaginal ring cores with an outer diameter of ⁇ 55 mm and a cross section diameter of ⁇ 5 mm were molded at approximately 175° C. and at ⁇ 5 tons of pressure.
- the mold was held at ⁇ 60° C. during the molding operation and was further cooled 30-40° C. with or without a chiller after injection over ⁇ 5 minutes prior to removal of the ring.
- the ring was then placed between two sheets of EVA film (4-5 mils thick, 9% vinyl acetate content), placed in a mold and compressed at 15-20 tons of force at temperatures sufficient to adhere the laminating layers to one another and the core ring (generally at 100-120° C. for EVA). Excess material was cut and trimmed, leaving a core-sheath ring.
- the photographs below shows the overall ring prior to trimming as well as a cross section showing the distinct core and sheath domains.
- the cutting and trimming operating is ultimately expected to be carried out using an automated die cutting system.
- Much larger batches of material up to 5 kg can be mixed at a time using scaled up dual asymmetric planetary mixing equipment and different geometries are accessible using appropriate molds (for example, rod-shaped) and the same fundamental molding and lamination process. Additionally, it is anticipated that the same process should also be applicable to other thermoplastic elastomers, particularly thermoplastic polyurethanes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmacologically active implants, in particular subcutaneous implants, intrauterine devices, and intravaginal rings, are provided herein. Methods for forming an active ingredient-containing core are described. Methods for laminating an active ingredient-containing core to form a rate-controlling sheath are also described.
Description
- This application claims benefit of U.S. Provisional Application No. 62/047,344, filed on Sep. 9, 2014 and which application is incorporated herein by reference. A claim of priority is made.
- Solid drug delivery implants are utilized to provide sustained release of an active agent or drug over a period of days, weeks, months, or years as an attractive alternative to more conventional dosage forms, such as oral or parenteral dosages. A few examples of such products include subcutaneous “rod” implants, intrauterine devices, and intravaginal rings (IVRs). In order to provide consistent and constant drug release rates a preferred approach is to embed the drug within a polymer matrix of material and encapsulate it within a polymer membrane or sheath to provide a barrier for controlled drug diffusion and release. Typically the drug is incorporated into the polymer by a hot melt extrusion process to produce drug-doped pellets. These pellets are then extruded to form the drug-filled core, and a rate-controlling sheath is coextruded over the drug-filled core. Drug-filled cores, and appurtenant sheaths, are extruded in lengths, typically with circular cross-sections. When continuous implant shapes are desired, the sheathed cores must be cut to length and the ends must be welded together.
- In cases where a very thin (<0.5 mm, frequently 0.10 mm or less) sheath thicknesses are advantageous or required, control of thickness during extrusion can be problematic and required expensive in-line process control and equipment. The extrusion process also subjects the drug to significant thermal loads which can cause a range of deleterious effects, including chemical degradation of the drug and/or matrix and sheath components, crystallization within the polymer matrix. Further, the process often demands relatively large amounts of material resulting in wasted active ingredients and polymer material. Additionally, coextrusion equipment and subsequent process steps (e.g. welding into rings) can also be expensive and engender process inefficiency.
- In general, this disclosure describes techniques for manufacturing active ingredient cores. Techniques further describe methods for laminating active ingredient cores to form a rate-controlling sheath. In particular, this disclosure describes techniques for manufacturing subcutaneous implants, intrauterine devices, and intravaginal rings (IVRs), although it should be noted that the techniques of this disclosure are generally applicable to pharmacologically active implants.
- According to an example of the disclosure, a method of forming a pharmacologically active homogenous core matrix mixture comprises combining one or more polymers with one or more active ingredients to form a mixture; and mixing the mixture sufficient to impart heat and until a homogenous mixture is achieved; wherein heat imparted to the mixture is sufficient to melt the polymer without substantially altering the pharmacological properties of the active ingredient.
- According to another example of the disclosure, a method of forming a rate-controlling release membrane over a pharmacologically active core comprises positioning a core between two layers film; applying one or more of heat and pressure to the core and film layers such that each film layer mechanically combines with one or more of the ring-shaped core and the opposite membrane film; and trimming excess film to form a sheath having a substantially uniform thickness.
- The details of one or more examples are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
- The accompanying drawings illustrate non-limiting example embodiments of the invention.
-
FIG. 1 illustrates a cross sectional side view of a ring-shaped implant, according to one or more embodiments of this disclosure. -
FIG. 2 illustrates a method for forming an inner core, according to one or more embodiments of this disclosure. -
FIG. 3A illustrates a method for laminating an inner core, according to one or more embodiments of this disclosure. -
FIG. 3B illustrates a perspective view of an inner core being positioned between sheath materials, according to one or more embodiments of this disclosure. -
FIG. 3C illustrates a perspective view of a post-combining product, according to one or more embodiments of this disclosure. -
FIG. 3D illustrates a cross-sectional view of a post-combining product, according to one or more embodiments of this disclosure. -
FIG. 3E illustrates a cross-sectional view of a post-combining product with excess material identified, according to one or more embodiments of this disclosure. - The present invention is described with reference to the attached figures, wherein like reference numerals are used throughout the figures to designate similar or equivalent elements. The figures are not drawn to scale and they are provided merely to illustrate the invention. Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide an understanding of the invention. One skilled in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or with other methods. In other instances, well-known structures or operations are not shown in detail to avoid obscuring the invention. The present invention is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.
- This disclosure provides novel solid drug delivery implants and methods of manufacture therefor. As used herein, “implants” can refer to an object which contacts the body of an animal or human, or an object which is positioned within an organ or an orifice. For example, an implant can be positioned within a mouth, within a vagina, underneath an epidermis, or within a uterus. Examples of bodily positions are non-limiting; embodiments provided herein can be utilized throughout a body as necessary or advantageous. Implants can include subcutaneous implants, intrauterine devices, and intravaginal rings (IVRs).
-
FIG. 1 illustrates a cross-sectional side view of animplant 100, comprising aninner core 110 and a rate-controllingsheath 120.Inner core 110 can comprise one or more polymer excipients and at least one active ingredient. The polymer fraction forms a matrix throughout which the one or more active ingredients are dispersed. In many embodiments, the active ingredient is substantially uniformly dispersed, such as having a material uniformity less than +/−5%, less than +/−4%, less than +/−3%, less than +/−2%, or less than +/−1%. Polymers can include thermoplastics such as thermoplastic urethanes, polyethylene terephthalate polyesters, silicone thermoplastics, LTV silicone elastomers, and polyamides. Specific examples of polymers can include polyoxymethylene, thermoplastic copolyester elastomer (TPC-ET), polyethylene homopolymer, poly(vinyl acetate) homopolymer, poly(lactic acid) homopolymer, poly(caprolactone), polypropylene, poly(ethylene oxide), poly(styrene), poly(vinyl chloride) poly lactic-co-glycolic acid, and ethylene vinyl acetate (EVA). EVA comprises ethylene and vinyl acetate, with a weight percent (wt. %) of vinyl acetate ranging from about 5 wt. % to about 40 wt. %, about 7 wt. % to about 34 wt. %, or about 9 wt. % to about 28 wt. %. - Active ingredients can include any pharmacologically active agents, such as contraceptive hormones. Contraceptive hormones can include estradiol, ethinyl estradiol, etonogestrel, progesterone, ethisterone, norethisterone acetate, norethynodrel, levonorgestrel, or gestodene, although others are similarly suitable as would be recognized by one of skill in the art after review of this disclosure.
Inner core 110 can further comprise opacifiers, such as barium sulfate, or dyes. -
Inner core 110 can have a cross-sectional shape which is circular, or polygonal. In some embodiments, a cross-sectional shape is chosen to accommodate manufacturing processes or equipment. The overall shape of theinner core 110 can be tubular or rod shaped, or a continuous shape. A continuous shape can include a circle, oval, triangle, square, or other polygons. Shapes can include a mixture of straight and curved edges, such as a semi-circle. Shapes can include irregular geometries which can be in some embodiments designed to match the contour of an implant positioning location within a body. - Rate-controlling
sheath 120 can comprise one or more polymers, such as those suitable for theinner core 110. Rate-controllingsheath 120 can comprise a similar composition to the polymer fraction of theinner core 110. In some embodiments, rate-controllingsheath 120 andinner core 110 share at least one common polymer component. Composition of the rate-controlling sheath can be determined based on permeability of one or more active ingredients. In some embodiments, the compositions of the rate-controllingsheath 120 is selected such that the rate controlling-sheath 120 can melt. Accordingly, in some embodiments, polymers such as silicone are not suitable for the rate-controllingsheath 120. In some embodiments, the rate-controlling sheath has a thickness of between about 1 mil to about 25 mils (about 0.0254 mm to about 0.635 mm). - As shown in
FIG. 2 , amethod 200 of forming an inner core can comprise low-heat mixing 210 inner core components to form a mixture, processing 220 the mixture after mixing, and forming the inner core 230. Inner core components can be supplied for mixing in powdered, pelleted, or liquid forms. One or more objectives of mixing 210 include removing air bubbles from the mixture, homogenizing the mixture to achieve suitable uniformity, elevating the temperature of the mixture above a melting point of at least one polymer. “Melting point” as used herein can refer to a melting point or a glass transition temperature. Homogenizing the mixture includes evenly dispersing the one or more active ingredients throughout the mixture. Mixing 210 can be accomplished via asymmetric mixing, wherein friction of mixing imparts heat on the mixture such that at least one polymer exceeds its melting point. - Asymmetric mixing advantageously imparts sufficient heat onto the mixture, while the heat of the mixture remains below a damaging heat threshold. Active ingredients, such as estradiol, can be heat sensitive, and appreciable chemical degradation of an active ingredient can define a damaging heat threshold. Asymmetric mixing is contactless, and relies on the movement of the vessel to initiate rapid spinning and shearing of a mixture contained within a vessel. As used herein, “contactless” describes the relationship between a mixture and a mixer wherein the only component contacting the mixture is the vessel. This is in contrast to other mixing methods, which use paddles, screws, or other mixing elements to which contact and mix a mixture. Asymmetric mixing can include dual asymmetric mixing. Speed and duration of mixing is controlled to achieve mixing objectives.
- An advantage of this approach is that a range of mix sizes is easily attainable by choosing the appropriate mix vessel for the mix size and cleaning can be minimized or eliminated entirely due to minimal contact surfaces. In some cases the heat and shear loads on fragile polymers or active ingredients can be reduced relative to other methods due to the rapid mixing. Vessels can be composed of a range of materials, including polypropylene, thermoplastic polyurethanes, glass, metals such as stainless steel or aluminum, polyethylene, polytetrafluoroethylene, or other suitable container materials. The vessel can comprise a number of materials which are disposable or reusable. Dual planetary mixers can be used. Examples of mixers include FlackTek SpeedMixers™ and Thinky mixers.
- Processing 220 can include allowing the mixture to cool under ambient conditions, or cooling the mixture using refrigerants, liquid nitrogen, or the like. Processing 220 can further comprise forming the cooled mixture into powders, granules, pellets, or pieces. An objective of processing 220 is to achieve a particle size which is suitable for forming 230 the inner core. In some embodiments a suitable particle diameter is less than 3 inches, less than 2 inches, or less than 1 inch. Forming the inner core 230 can comprise injection molding, although other methods can be suitable. An objective of forming the inner core 230 includes remaining below a damaging heat threshold.
- As shown in
FIG. 3A , amethod 300 of laminating an inner core can comprise positioning 310 an inner core between two surfaces of rate-controlling sheath material, combining 320 the inner core and sheath material, and trimming 330 excess sheath material.FIG. 3B shows aninner core 110 being positioned 310 betweensheath materials inner core 110. Combining 320 the inner core and sheath material can comprise thermal and/or pressure lamination. - The use of lamination to create dosage forms for pharmaceuticals is novel in the industry, as coextrusion has been the manufacturing method of choice due to familiarity of the technology. In instances where lamination has been employed, the same has been used solely to affect surfaces properties (e.g., wear, resistance, feel, etc.) of products. Lamination can be preferable to coextrusion as it is time efficient, heat and material efficient, and allows for superior operating temperature management and control and uniformity of sheath thickness. Controlling sheath uniformity and thickness is critical as it directly impacts drug release rates and overall implant efficacy and safety. Lamination additionally allows for thinner sheaths to be manufactured, increasing functionality of implants (e.g., drug release rates and use duration). Further, lamination encapsulates an inner core ring as a whole, rather than utilizing a welded joint which can affect drug release rate.
- Lamination according to
method 300 can be conducted at high pressures, such as at 15 to 20 tons of force. Temperature can include temperatures above the film material's melting point. For example, when EVA is a film component, temperatures of 100-120 C can be used. In many embodiments, an operating temperature exceeds the melting point of one or more polymers by less than about 1% of the melting point temperature, less than about 2.5% of the melting point temperature, less than about 5% of the melting point temperature, or less than about 10% of the melting point temperature. When one or more films contain multiple polymer components, a temperature can be chosen to exceed the melting point of one polymer component, of a plurality of polymer components, or all polymer components. A temperature can also be chosen such that the melting point of a core component is not exceeded. When a temperature is used which exceeds the melting point of a core component, lamination process time and/or compressing pressure can be chosen to complement the process temperature in order to avoid chemical degradation and/or physical deformation of the core. Films can combine by one or more of adhering to the opposite film, or adhering to theinner core 110. -
FIG. 3C illustrates a post combining 320product 325.FIG. 3D illustrates a cross-sectional view of a post-combing 320product 325 which comprises aninner core 110 and a rate-controllingsheath 120.FIG. 3E illustrates a cross-sectional view of a post-combining 320product 325, whereinexcess sheath material 125 is identified.Excess material 125 can be defined as material not substantially contributing to an extrapolated contour of the core. Excess material can also be defined as material which does not provide a consistent sheath thickness. Trimming 330 excess sheath material can be accomplished using a die cutting system, or other suitable means. - Approximately 50 g of ethylene vinyl acetate (28% vinyl acetate content) polymer (pellets or granules) was measured into a 150 mL cylindrical container after which 50-250 mg of sex hormones such as ethinyl estradiol and/or etonorgestrel powder or opacifier such as barium sulfate were added. The container was placed in a dual asymmetric mixer (Flaktek SpeedMixer) and mixed for 2-10 minutes at up to 3000 RPM. Upon removal the EVA had melted (estimated temperature 100-120° C.) and the drug was uniformly dispersed throughout the melt. Drug content analysis performed using inductively coupled plasma—optical emission spectroscopy revealed that material uniformity was approximately +/−2%.
- After the melt was allowed to cool, the material was processed into granular materials suitable for injection molding by cooling the polymer and processing using with an IKA bladed mill. When EVA was used, the polymer was cooled using liquid nitrogen before and/or during milling. Following milling, particle size was generally less than 0.75 in diameter, though many smaller particles were present.
- After milling, this ground material was transferred to an injection molding press and vaginal ring cores with an outer diameter of ˜55 mm and a cross section diameter of ˜5 mm were molded at approximately 175° C. and at ˜5 tons of pressure. The mold was held at ˜60° C. during the molding operation and was further cooled 30-40° C. with or without a chiller after injection over ˜5 minutes prior to removal of the ring. The ring was then placed between two sheets of EVA film (4-5 mils thick, 9% vinyl acetate content), placed in a mold and compressed at 15-20 tons of force at temperatures sufficient to adhere the laminating layers to one another and the core ring (generally at 100-120° C. for EVA). Excess material was cut and trimmed, leaving a core-sheath ring.
- The photographs below shows the overall ring prior to trimming as well as a cross section showing the distinct core and sheath domains. The cutting and trimming operating is ultimately expected to be carried out using an automated die cutting system. Much larger batches of material (up to 5 kg) can be mixed at a time using scaled up dual asymmetric planetary mixing equipment and different geometries are accessible using appropriate molds (for example, rod-shaped) and the same fundamental molding and lamination process. Additionally, it is anticipated that the same process should also be applicable to other thermoplastic elastomers, particularly thermoplastic polyurethanes.
Claims (8)
1. A method of forming a pharmacologically active homogenous core matrix mixture, the method comprising:
combining one or more polymers with one or more active ingredients to form a mixture; and
mixing the mixture sufficient to impart heat and until a homogenous mixture is achieved; wherein heat imparted to the mixture is sufficient to melt the polymer without substantially altering the pharmacological properties of the active ingredient.
2. The method of claim 1 , wherein mixing is accomplished via a dual asymmetric mixer.
3. The method of claim 1 , wherein mixing is contactless.
4. The method of claim 1 , wherein the homogenous mixture has a material uniformity of less than +/−5%.
5. The method of claim 1 , further comprising combining the one or more polymers and one or more active ingredients with one or more of an opacifier or a dye.
6. The method of claim 1 , further comprising cooling the mixture.
7. The method of claim 5 , further comprising processing the cooled mixture to achieve a mean particle diameter of less than 2 inches.
8. The method of claim 1 , wherein the one or more active ingredients comprises one or more of estradiol, ethinyl estradiol, etonogestrel, progesterone, ethisterone, norethisterone acetate, norethynodrel, levonorgestrel, or gestodene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/618,339 US20170273900A1 (en) | 2014-09-08 | 2017-06-09 | Methods for manufacturing implants |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047344P | 2014-09-08 | 2014-09-08 | |
US14/847,782 US10226419B2 (en) | 2014-09-08 | 2015-09-08 | Methods for manufacturing implants |
US15/618,339 US20170273900A1 (en) | 2014-09-08 | 2017-06-09 | Methods for manufacturing implants |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/847,782 Division US10226419B2 (en) | 2014-09-08 | 2015-09-08 | Methods for manufacturing implants |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170273900A1 true US20170273900A1 (en) | 2017-09-28 |
Family
ID=55436467
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/847,782 Expired - Fee Related US10226419B2 (en) | 2014-09-08 | 2015-09-08 | Methods for manufacturing implants |
US15/618,339 Abandoned US20170273900A1 (en) | 2014-09-08 | 2017-06-09 | Methods for manufacturing implants |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/847,782 Expired - Fee Related US10226419B2 (en) | 2014-09-08 | 2015-09-08 | Methods for manufacturing implants |
Country Status (1)
Country | Link |
---|---|
US (2) | US10226419B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11180670B2 (en) | 2019-03-28 | 2021-11-23 | Lawrence Livermore National Security, Llc | Three-dimensional porous siloxanes using leachable porogen particles |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019275409A1 (en) * | 2018-05-24 | 2020-07-16 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3926188A (en) * | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
US4945132A (en) | 1982-09-29 | 1990-07-31 | Wilkus Edward V | Crosslinked polymer interdispersions, related compositions and method of making same |
US4758435A (en) | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
US4964416A (en) | 1988-11-15 | 1990-10-23 | Foldesy Robin G | Condom articles, and apparatus and method for making and using the same |
US6264638B1 (en) | 1989-12-07 | 2001-07-24 | Ultrafem, Inc. | Intravaginal drug delivery system and discharge collection device |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
DE4230588C1 (en) * | 1992-09-12 | 1993-10-07 | Lohmann Therapie Syst Lts | Dexpanthenol-containing plaster for the transdermal application of steroid hormones and process for its production |
US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
CN103329049B (en) | 2011-01-31 | 2016-03-16 | 惠普发展公司,有限责任合伙企业 | Liquid electrophotographic ink and preparation method thereof |
-
2015
- 2015-09-08 US US14/847,782 patent/US10226419B2/en not_active Expired - Fee Related
-
2017
- 2017-06-09 US US15/618,339 patent/US20170273900A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
Morrow et al (European Journal of Pharmaceutics and Biopharmaceutics 77 (2011) 3–10). * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11180670B2 (en) | 2019-03-28 | 2021-11-23 | Lawrence Livermore National Security, Llc | Three-dimensional porous siloxanes using leachable porogen particles |
Also Published As
Publication number | Publication date |
---|---|
US10226419B2 (en) | 2019-03-12 |
US20160067178A1 (en) | 2016-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Genina et al. | Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devices | |
Kempin et al. | Immediate release 3D-printed tablets produced via fused deposition modeling of a thermo-sensitive drug | |
Repka et al. | Applications of hot-melt extrusion for drug delivery | |
US20170273900A1 (en) | Methods for manufacturing implants | |
JP6251396B2 (en) | Drug delivery system | |
CN101827569B (en) | Drug delivery system | |
CN1794974B (en) | Drug delivery system | |
JP2021059540A (en) | Dosage form incorporating amorphous drug solid solution | |
CN101541301B (en) | Helically-shaped drug delivery system | |
ES2598235T3 (en) | Solid delay formulations based on solid dispersions | |
EP2814458B1 (en) | Drug delivery system for use in contraception comprising a core and a sheath | |
CN1933820A (en) | Drug delivery system based on polyethylene vinylacetate copolymers | |
EP3247327B1 (en) | Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing | |
MX2008012264A (en) | Stabilized compositions containing alkaline labile drugs. | |
Long et al. | Development of customised 3D printed biodegradable projectile for administrating extended-release contraceptive to wildlife | |
Feng et al. | Twin-screw extrusion of sustained-release oral dosage forms and medical implants | |
WO2018197395A1 (en) | Vaginal ring for the simultaneous release of two active ingredients | |
US20190328657A1 (en) | Hormonal contraception using a vaginal ring which releases estriol | |
Loxley | Devices and implants prepared using hot melt extrusion | |
GB2178658A (en) | Sustained release tablets and a method of manufacture thereof | |
Keen et al. | Melt extruded controlled release dosage forms | |
US11413247B2 (en) | Batch-wise melt extrusion process and device for preparing a solid dispersion | |
CN107049995A (en) | A kind of method for preparing Thermo-sensitive insoluble drug release composite | |
Li et al. | Hot-Melt Extrusion: An Emerging Manufacturing Technology for Drug Products | |
EP3154532A1 (en) | Microcapillary polymer films for drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PROMED PHARMA,LLC, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARPS, JAMES H.;PETERSEN, MATTHEW;REEL/FRAME:042660/0367 Effective date: 20150923 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |